1. Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37(5):729–735
2. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132(6):425–434
3. Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N (1999) Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud’s phenomenon. Minerva Cardioangiol 47(5):137–143
4. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, Finke J, Peter HH, van Laar J, Breedveld FC et al (2001) Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 60(6):577–584
5. Clegg DO, Reading JC, Mayes MD, Seibold JR, Harris C, Wigley FM, Ward JR, Pisko EJ, Weisman MH, Lee P et al (1994) Comparison of amino-benzoate potassium and placebo in the treatment of scleroderma. J Rheumatol 21(1):105–110